Black Diamond Therapeutics (BDTX)
(Delayed Data from NSDQ)
$3.75 USD
+0.09 (2.46%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $3.74 -0.01 (-0.27%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.75 USD
+0.09 (2.46%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $3.74 -0.01 (-0.27%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Zacks News
All You Need to Know About Black Diamond (BDTX) Rating Upgrade to Buy
by Zacks Equity Research
Black Diamond (BDTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Should You Buy Black Diamond Therapeutics (BDTX) Ahead of Earnings?
by Zacks Equity Research
Black Diamond Therapeutics (BDTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Black Diamond (BDTX) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Black Diamond (BDTX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Does Black Diamond (BDTX) Have the Potential to Rally 152.96% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Black Diamond (BDTX) points to a 153% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Black Diamond (BDTX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Black Diamond (BDTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Predict a 129.25% Upside in Black Diamond (BDTX): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 129.3% in Black Diamond (BDTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
How Much Upside is Left in Black Diamond Therapeutics (BDTX)? Wall Street Analysts Think 95.93%
by Zacks Equity Research
The mean of analysts' price targets for Black Diamond Therapeutics (BDTX) points to a 95.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Down 32.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX)
by Zacks Equity Research
Black Diamond (BDTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
What's in the Cards for Doximity (DOCS) in Q2 Earnings?
by Zacks Equity Research
Doximity's (DOCS) products like Doximity Dialer and Residency Navigator have been in focus and we expect both to have generated significant revenues during the fiscal second quarter.
What's in Store for Canopy Growth (CGC) in Q2 Earnings?
by Zacks Equity Research
Canopy Growth's (CGC) newly-added Ace Valley and Supreme Cannabis hold part of the company's market share in fiscal Q2.
Is a Beat in Store for Zoetis (ZTS) This Earnings Season?
by Zacks Equity Research
Zoetis (ZTS) is set to report earnings and revenues, and provide updates on its diversified product portfolio when it releases third-quarter 2021 results.
Is a Surprise Coming for Black Diamond Therapeutics (BDTX) This Earnings Season?
by Zacks Equity Research
Black Diamond Therapeutics (BDTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Coupa Software's (COUP) BSM Platform Adopted by World Vision
by Zacks Equity Research
Coupa Software (COUP) is likely to benefit from coronavirus-induced robust demand for the company's BSM offering.
Coupa Software (COUP) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Coupa Software's (COUP) first-quarter fiscal 2021 results benefit from coronavirus crisis-triggered robust demand for Coupa BSM and market traction of Coupa Pay offerings.
How Black Diamond Therapeutics (BDTX) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Black Diamond Therapeutics (BDTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Zacks.com featured highlights include: ThermoGenesis, Minerva, Sprout Social, Black Diamond and Zynex
by Zacks Equity Research
Zacks.com featured highlights include: ThermoGenesis, Minerva, Sprout Social, Black Diamond and Zynex
5 Stocks With Recent Price Strength Amid Disappointing Data
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Black Diamond Therapeutics, Inc. (BDTX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Black Diamond Therapeutics, Inc. (BDTX).
New Strong Buy Stocks for April 27th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: